DRUG NAME: Cefoxitin

---

Therapeutic Class:

---

Subclass:

---

Schedule (India):

---

Route(s)

• IV (intravenous — slow bolus over 3–5 minutes, or intermittent infusion over 15–30 minutes, or continuous infusion in select settings)
• IM (intramuscular — deep injection; may be reconstituted with lidocaine for pain reduction)

---

Biosimilar Status:

---

Formulations Available in India

---

PHARMACOKINETICS

---

---

---

---

ANTIMICROBIAL SPECTRUM TABLE

---

ANTIMICROBIAL STEWARDSHIP NOTE

1. Niche agent, not empirical first-line. Cefoxitin occupies a specific clinical niche — its value lies in combined aerobic gram-negative + anaerobic coverage without anti-pseudomonal or anti-MRSA activity. It is NOT a general-purpose cephalosporin and should not replace cefazolin (surgical prophylaxis for clean procedures) or ceftriaxone (empirical gram-negative coverage) in their primary roles.
2. Narrower-spectrum alternatives should be preferred when anaerobic coverage is not needed:
   • Clean surgical prophylaxis (e.g., orthopaedic, vascular): Cefazolin is preferred — narrower spectrum, longer half-life, lower cost.
   • Uncomplicated UTI: Nitrofurantoin, fosfomycin, or targeted oral agents — cefoxitin reserved for complicated/resistant UTIs.
   • Community-acquired pneumonia: Cefoxitin is NOT appropriate — use amoxicillin-clavulanate, ceftriaxone with macrolide, or respiratory fluoroquinolone.
3. Carbapenem-sparing potential: In the Indian AMR context with ESBL prevalence rates of 50–70% among hospital Enterobacterales (ICMR AMR Annual Report 2022), cefoxitin offers a potential carbapenem-sparing option for documented ESBL infections when in-vitro susceptibility is confirmed. This stewardship advantage should be actively utilised to reduce carbapenem selection pressure.
4. Culture-directed use is strongly recommended for most therapeutic indications (as opposed to surgical prophylaxis, which is empirical by nature). Given variable susceptibility patterns in Indian settings, empirical cefoxitin use should be limited to situations with high pre-test probability of mixed aerobic-anaerobic infection (intra-abdominal, pelvic).
5. Duration discipline: Due to the short half-life requiring q6–8h dosing, unnecessary prolongation of IV cefoxitin therapy increases nursing burden and cost. Actively pursue IV-to-oral step-down as soon as clinical criteria are met (see Step-Down Criteria under each indication).

---

ADULT INDICATIONS + DOSING

---

Primary Indication 1: SURGICAL PROPHYLAXIS — Clean-Contaminated and Contaminated Procedures

---

1. When to prefer cefoxitin over alternatives:
   • (a) Advantage over cefazolin: Cefoxitin provides reliable B. fragilis coverage, which cefazolin lacks entirely. For procedures entering or adjacent to the colon, vaginal canal, or other sites with high anaerobic burden, cefoxitin is superior as a single-agent prophylactic.
   • (a) Advantage over cefuroxime + metronidazole combination: Cefoxitin achieves comparable aerobic + anaerobic coverage in a single agent, reducing complexity and potentially reducing nursing preparation time (one drug instead of two).
   • (b) Cefoxitin is first-line for colorectal and gynaecological surgical prophylaxis. For clean procedures, it is NOT first-line (cefazolin is preferred).
   • © Specific comparison: Preferred over cefazolin for colorectal/gynaecological procedures. Equivalent to cefuroxime + metronidazole (single-agent convenience). NOT preferred over cefazolin for clean orthopaedic/vascular/cardiac procedures.
2. When NOT to use: Clean procedures without anaerobic contamination risk (cefazolin is sufficient and preferred). Patient with documented cephalosporin allergy (see Part 4). Should not be used as prolonged post-operative therapeutic prophylaxis — this is a common misuse.
3. NLEM India status: ⚠️ Cefoxitin is NOT listed in NLEM India 2022. Cefazolin (for clean procedures) and metronidazole (for anaerobic coverage) are NLEM-listed and available in government supply — cefoxitin may not be available at all PHC/CHC/district hospitals.
4. Time to expected clinical response: Not applicable for prophylaxis (no pre-existing infection). Aim is prevention. If SSI develops despite prophylaxis, cefoxitin failure should be considered and therapeutic cultures obtained.
5. Criteria for treatment failure: Development of SSI despite appropriate prophylaxis. Obtain wound culture and switch to targeted therapy. Re-evaluate if re-dosing was adequate intraoperatively.
6. Mandatory baseline investigations: No specific investigations required before a single prophylactic dose. Routine pre-operative workup (CBP, RFT, coagulation) is part of standard surgical assessment.
7. Specialist initiation: No — surgical prophylaxis decisions made by the operating surgeon and/or anaesthesiologist. No infectious disease consultation required for prophylaxis.
8. Indian guideline source: FOGSI guidelines on surgical prophylaxis in gynaecological procedures; API Textbook of Medicine — Surgical Infections chapter; hospital-specific antibiotic policy manuals (AIIMS, PGIMER, CMC Vellore).
9. Key disease-specific safety warning: ⚠️ Short half-life (~45 min) mandates re-dosing every 2 hours during prolonged surgery. Failure to re-dose is a common cause of prophylaxis failure, particularly in long colorectal or hepatobiliary procedures. Anaesthesia teams must set re-dosing reminders.
10. Common scenarios requiring dose adjustment: Morbid obesity (increase to 2–3 g); renal impairment (see Part 3 — relevant only if prophylaxis extended beyond single dose); elderly patients (dose per renal function).
11. Common investigation misconception flag: ℹ️ Post-operative CRP or procalcitonin measured within 24–48 hours of surgery is normally ELEVATED due to surgical trauma — this does NOT indicate SSI or prophylaxis failure and should not prompt antibiotic escalation.

---

Primary Indication 2: INTRA-ABDOMINAL INFECTIONS — Community-Acquired, Polymicrobial

---

1. When to prefer cefoxitin over alternatives:
   • (a) Advantage over ceftriaxone + metronidazole: Single-agent coverage of both aerobic gram-negatives and anaerobes (fewer drugs, simpler regimen). However, gram-negative spectrum is narrower than ceftriaxone. For community-acquired mild-to-moderate infections in non-critically-ill patients, cefoxitin monotherapy is a reasonable option.
   • (a) Advantage over piperacillin-tazobactam: Narrower spectrum (stewardship advantage). Avoids unnecessary anti-pseudomonal and anti-enterococcal coverage for community-acquired infections.
   • (a) Advantage over carbapenems (meropenem, ertapenem): Significant carbapenem-sparing benefit — avoids selection pressure for CRE. Preferred when source control is adequate and infection is community-acquired.
   • (b) Cefoxitin is an acceptable alternative (not clearly first-line) for community-acquired intra-abdominal infections. API Textbook and AIIMS protocols list cefoxitin as an option alongside ceftriaxone + metronidazole and piperacillin-tazobactam.
   • © Compared against: Ceftriaxone + metronidazole (most commonly used in Indian practice), piperacillin-tazobactam, ertapenem, meropenem.
   • No specific advantage over ceftriaxone + metronidazole for most community-acquired intra-abdominal infections. Consider cefoxitin primarily when: single-agent simplicity is desired, OR as a carbapenem-sparing option for documented ESBL susceptibility.
2. When NOT to use:
   • ⛔ Healthcare-associated / nosocomial intra-abdominal infections (high probability of Pseudomonas, Enterococcus, MRSA, CRE — none covered by cefoxitin).
   • ⛔ Patients with septic shock or haemodynamic instability (use broader-spectrum empirical therapy initially — cefoxitin can be considered for de-escalation once cultures available).
   • ⛔ Suspected or confirmed biliary infections with hepatic abscess and cholangitis (may need broader coverage including anti-enterococcal activity in some protocols).
   • ⛔ Inadequate source control (antibiotic therapy alone is insufficient regardless of agent).
3. NLEM India status: ⚠️ Cefoxitin NOT listed in NLEM 2022. Ceftriaxone and metronidazole (both NLEM-listed) remain the most accessible combination in government hospital settings.
4. Time to expected clinical response: Clinical improvement (defervescence, resolving peritoneal signs, downtrending WBC/TLC) expected within 48–72 hours if source control is adequate. If no improvement by 72 hours: reassess source control adequacy, obtain repeat imaging, and review culture results.
5. Criteria for treatment failure: No clinical improvement by 72 hours; persistent/worsening sepsis parameters; new intra-abdominal collection on imaging; culture revealing resistant organism. Action: broaden therapy (escalate to carbapenem or piperacillin-tazobactam); reassess source control; consider repeat surgical intervention.
6. Mandatory baseline investigations: MANDATORY: CBP with differential, serum creatinine/eGFR (for dose adjustment), blood cultures (if septic), peritoneal/abscess fluid culture and sensitivity. RECOMMENDED: CRP/procalcitonin (baseline for trending), LFT, serum lactate (if sepsis suspected), abdominal imaging (CT or USG).
7. Specialist initiation: For mild-to-moderate community-acquired infections: Can be initiated by the operating surgeon or admitting physician. For complicated infections requiring ICU care: Infectious disease consultation recommended.
8. Indian guideline source: API Textbook of Medicine — chapter on Intra-Abdominal Infections; AIIMS Antimicrobial Guidelines (list cefoxitin as an option for community-acquired IAI); SIS (Surgical Infection Society) guidelines adapted in Indian surgical practice.
9. Key disease-specific safety warning: ⚠️ Clostridioides difficile–associated diarrhoea (CDAD) risk exists with cefoxitin as with all broad-spectrum antibiotics. Monitor for new-onset watery diarrhoea during or after therapy. Cefoxitin disrupts normal colonic flora and may select for C. difficile despite having no direct activity against it.
10. Common scenarios requiring dose adjustment: Renal impairment (see Part 3). Morbid obesity (use 2 g q6h). Augmented renal clearance in young ICU patients (use 2 g q6h; consider extended infusion).
11. Common investigation misconception flag: ℹ️ A single elevated CRP alone is NOT sufficient to diagnose treatment failure — CRP remains elevated for 3–5 days after source control even with successful treatment. Trend CRP over 48–72 hours rather than using a single value.

---

---

Primary Indication 3: PELVIC INFLAMMATORY DISEASE (PID) AND GYNAECOLOGICAL INFECTIONS

---

---

• Inpatient PID / TOA: IV cefoxitin until ≥48 hours of clinical improvement → oral step-down with doxycycline 100 mg BD ± metronidazole 500 mg BD to complete 14 days total.
• Post-partum / post-caesarean endometritis: IV therapy until afebrile and asymptomatic for 48 hours. Total IV duration typically 3–5 days. Oral step-down may not be needed if rapid resolution — clinical judgment. If myometritis or sepsis: longer course.

---

1. When to prefer cefoxitin over alternatives:
   • (a) Advantage over ceftriaxone (for PID): Cefoxitin provides better anaerobic coverage (B. fragilis group), which is important because PID is a polymicrobial infection where anaerobes play a significant pathogenic role. Ceftriaxone does NOT cover B. fragilis.
   • (a) Advantage over fluoroquinolones: With N. gonorrhoeae fluoroquinolone resistance >50% in Indian isolates (ICMR/NACO data), cefoxitin (active against N. gonorrhoeae) is more reliable for empirical gonorrhoeal coverage.
   • (b) Cefoxitin is a first-line option for the outpatient PID IM regimen (alongside the alternative ceftriaxone-based regimen). For inpatient PID/endometritis: first-line option per CDC/FOGSI-endorsed protocols.
   • © Compared against: Ceftriaxone 250–500 mg IM single dose + doxycycline ± metronidazole (alternative outpatient PID regimen); clindamycin + gentamicin (alternative inpatient PID regimen); ampicillin-sulbactam + doxycycline (alternative inpatient regimen).
2. When NOT to use:
   • ⛔ IUD-related PID with suspected Actinomyces — cefoxitin does not reliably cover Actinomyces israelii; high-dose penicillin preferred.
   • ⛔ Suspected pelvic TB — requires ATT, not antibacterial therapy.
   • ⛔ If patient has recently (<3 months) been hospitalised or had instrumentation — consider healthcare-associated flora (Pseudomonas, Enterococcus) and broaden coverage.
3. NLEM India status: Cefoxitin NOT in NLEM 2022. Doxycycline and metronidazole (used in the combination regimen) are NLEM-listed. Ceftriaxone (alternative) is NLEM-listed.
4. Time to expected clinical response: Outpatient PID: symptom improvement expected within 72 hours of starting the regimen. Inpatient PID/endometritis: defervescence and pain reduction expected within 48–72 hours. TOA: may require longer (5–7 days of IV therapy; consider drainage if no response).
5. Criteria for treatment failure: Outpatient PID: no improvement or worsening after 72 hours — hospitalise and switch to IV regimen. Inpatient: persistent fever and tenderness after 72 hours of appropriate IV therapy — obtain imaging to rule out undrained TOA; consider surgical intervention; broaden antimicrobial coverage.
6. Mandatory baseline investigations: MANDATORY: Pregnancy test (⛔ rule out ectopic pregnancy before treating as PID). RECOMMENDED: Pelvic USG (rule out TOA); endocervical NAAT for N. gonorrhoeae and C. trachomatis; HIV screening; syphilis serology; CBP; CRP. Note: treat partner(s) empirically for N. gonorrhoeae and C. trachomatis.
7. Specialist initiation: Outpatient PID: can be managed by trained primary care physician or O&G practitioner. Inpatient PID, TOA, post-surgical infections: gynaecology specialist management.
8. Indian guideline source: FOGSI Clinical Practice Guidelines on PID Management; CDC STI Treatment Guidelines 2021 (widely adopted in Indian O&G practice); API Textbook of Medicine — STI chapter.
9. Key disease-specific safety warning: ⚠️ Always rule out ectopic pregnancy before initiating PID treatment — ectopic pregnancy can mimic PID clinically. ⚠️ Partner notification and treatment is essential — PID caused by STIs will recur if partners are not treated.
10. Common scenarios requiring dose adjustment: Renal impairment (adjust per eGFR — see Part 3). No hepatic adjustment needed.
11. Common investigation misconception flag: ℹ️ A normal WBC/TLC does NOT rule out PID. Clinical diagnosis (cervical motion tenderness, adnexal tenderness, uterine tenderness) is sufficient to initiate empirical treatment. Waiting for investigations should NOT delay treatment.

---

Primary Indication 4: OTHER APPROVED INDICATIONS — Complicated Urinary Tract Infections, Skin & Soft Tissue Infections, Bone & Joint Infections, Lower Respiratory Tract Infections

1. When to prefer cefoxitin: No specific advantage over first-line agents for any of these indications in routine practice. Consider only when: (a) culture-directed therapy confirms cefoxitin susceptibility AND patient cannot receive preferred alternatives, OR (b) mixed aerobic-anaerobic infection requiring single-agent coverage.
2. When NOT to use: As empirical monotherapy for any of these conditions without culture guidance. Not appropriate for MRSA infections, Pseudomonas infections, or atypical infections.
3. Mandatory baseline investigations: Culture and sensitivity (MANDATORY for all these indications before starting cefoxitin). CBP, RFT. Imaging as appropriate (USG for abscess, X-ray/MRI for bone infections, chest X-ray for LRTI).
4. Specialist initiation: Bone and joint infections: infectious disease/orthopaedic specialist. Others: can be managed by treating physician with culture guidance.

---

Secondary Indications — Adults Only (Off-label)

---

Secondary Indication 1: ESBL-Producing Enterobacterales Infections — Carbapenem-Sparing Targeted Therapy

• ⚠️ Must confirm in-vitro susceptibility — do NOT use empirically. Not all ESBL producers are cefoxitin-susceptible; co-production of AmpC beta-lactamases or porin mutations can confer resistance.
• ⚠️ Currently NOT recommended for ESBL bloodstream infections with high-inoculum sites (e.g., undrained abscesses, endovascular infections) due to concern about inoculum effect — in-vitro susceptibility may not translate to in-vivo efficacy at high bacterial burden.
• 💡 Best evidence is for ESBL UTIs (low inoculum, high urinary drug concentrations far exceeding MIC). This is where the carbapenem-sparing strategy is most robust.
• For ESBL BSI: consider as de-escalation from carbapenems after clinical improvement, rather than as initial definitive therapy. MERINO-3 data awaited.
• Indian relevance: With ESBL prevalence among hospital E. coli isolates at 50–70% (ICMR AMR 2022) and rising carbapenem resistance, every opportunity to avoid carbapenem use is a stewardship imperative. Cefoxitin offers a practical carbapenem-sparing option when susceptibility is confirmed.

---

Secondary Indication 2: Non-Tuberculous Mycobacterial Infections — Mycobacterium abscessus Complex

• ⚠️ Doses used for M. abscessus (up to 12 g/day) are significantly higher than for conventional bacterial infections. Monitor renal function closely during therapy.
• ℹ️ M. abscessus infections are rare but increasingly recognised in India. DST (drug susceptibility testing) including cefoxitin should be performed through reference mycobacteriology laboratories.
• High-dose cefoxitin at 12 g/day requires careful attention to sodium load (cefoxitin sodium contains ~2.3 mEq Na⁺ per gram) — relevant for patients with heart failure or fluid overload.

---

MISSED DOSE / DELAYED DOSE GUIDANCE

• ⚠️ For critically ill / septic patients: Missed doses of cefoxitin have direct clinical consequences because the short half-life (~45 minutes) means bactericidal serum concentrations are lost rapidly. Minimise dose delays. Consider continuous infusion protocols if doses are frequently delayed due to nursing workflow constraints.
• For beta-lactams with time-dependent killing: Maintaining dosing intervals is more important than achieving high peak concentrations. A delayed dose that is “squeezed in” too close to the next dose is preferable to skipping entirely.
• For the single-dose IM PID regimen: If the dose is administered as intended (single dose), missed dose guidance is not applicable. If the IM injection fails (e.g., vomiting of concurrent probenecid dose within 30 minutes): re-administer probenecid; do not repeat cefoxitin IM injection if it was successfully administered intramuscularly.

• Resume at the same dose and frequency — no re-titration needed.
• Assess whether the gap in therapy has led to clinical deterioration and whether treatment duration needs to be extended.
• For NTM (M. abscessus) treatment: interruptions may compromise the multi-drug regimen. Consult treating specialist.

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE

---

IV ADMINISTRATION

• Total daily dose: 60 × 200 = 12,000 mg = 12 g/day.
• Per dose (q6h): 12,000 ÷ 4 = 3,000 mg = 3 g per dose.
• Reconstitute: One 2 g vial (in 20 mL SWFI) + one 1 g vial (in 10 mL SWFI) → combine and dilute in 100 mL NS. Infuse over 30 minutes q6h.
• ⚠️ Sodium load at 12 g/day: approximately 12 × 2.3 mEq = 27.6 mEq Na⁺/day from cefoxitin alone.

---

IM ADMINISTRATION

---

STABILITY AFTER RECONSTITUTION

---

Y-SITE / LINE COMPATIBILITY

---

SPECIAL ADMINISTRATION NOTES

• Extravasation risk: Low — cefoxitin is not a vesicant. If extravasation occurs, apply warm compress and monitor site. No specific antidote required.
• Allergic/anaphylactic preparedness: As with all beta-lactams, have resuscitation equipment and adrenaline (epinephrine) available at the site of IV/IM administration, especially for the first dose.
• Thrombophlebitis: Prolonged peripheral IV administration (>48–72 hours via same cannula) may cause phlebitis. Rotate IV sites every 48–72 hours. Consider central line if prolonged (>5 days) IV therapy anticipated.
• Multi-dose vial: Cefoxitin vials are single-use (no preservative). ⛔ Do NOT store reconstituted portion for later use from the same vial in multi-patient settings — contamination risk.
• Enteral tube compatibility: Not applicable (parenteral-only drug).

---

STORAGE

---

PAEDIATRIC DOSING (Specialist Only)

General Notes

• Renal function: Serum creatinine and estimated GFR (Schwartz formula for children) before initiation and at least weekly during prolonged therapy. Children have higher GFR per body surface area than adults — standard adult eGFR calculators (CKD-EPI, Cockcroft-Gault) are NOT appropriate for children.
• Haematological: CBP at baseline and weekly if therapy exceeds 7 days — monitor for leucopaenia, thrombocytopenia (rare but reported with prolonged beta-lactam use).
• IV site monitoring: Children are prone to phlebitis and extravasation. Inspect cannula site every 4–6 hours. Rotate peripheral IV sites every 48–72 hours. Use mid-line or PICC if prolonged course anticipated.
• Fluid and sodium load: At 160 mg/kg/day, cefoxitin sodium contributes ~2.3 mEq Na⁺ per gram. For a 20 kg child receiving 3.2 g/day: approximately 7.4 mEq Na⁺ from drug alone. Clinically significant in neonates and infants with fluid restrictions or congenital heart disease.
• Diarrhoea monitoring: Monitor stool frequency and consistency. C. difficile–associated diarrhoea can occur in children, though less commonly than in adults. Test for C. difficile toxin if ≥3 watery stools/day or bloody diarrhoea develops during or within 4 weeks of therapy.

• ℹ️ Cefoxitin is available ONLY as a parenteral formulation (powder for injection). There is no oral liquid, dispersible tablet, or oral suspension form.
• Paediatric use therefore requires IV access or IM injection — practical limitation for outpatient and community-based paediatric care.
• Palatability is not a concern (parenteral-only drug), but IM injection pain is a significant concern in young children.
• 💡 IM injection in children: Reconstitute with 0.5% lidocaine (preservative-free, without epinephrine) to reduce pain at injection site. ⛔ Do NOT use lidocaine for IV reconstitution. Maximum IM volume per site in children: Infants (<1 year): 0.5 mL per site. 1–3 years: 1 mL per site. 3–6 years: 1.5 mL per site. 6–12 years: 2 mL per site. >12 years: 2.5 mL per site. If calculated volume exceeds per-site limit, split into two injection sites.

---

Neonatal Dosing

• Culture-confirmed infection with organism susceptible to cefoxitin but resistant to standard neonatal antibiotics
• Intra-abdominal pathology in neonate (necrotising enterocolitis [NEC] with perforation, Hirschsprung-associated enterocolitis) requiring anaerobic + aerobic coverage — in this specific scenario, cefoxitin offers a meaningful clinical advantage
• Documented ESBL-producing Enterobacterales infection susceptible to cefoxitin — carbapenem-sparing strategy in NICU with high CRE prevalence

• ⚠️ Bilirubin displacement: Cefoxitin is approximately 65–80% protein-bound. In neonates with hyperbilirubinaemia, there is a theoretical risk of bilirubin displacement from albumin binding sites, potentially increasing free bilirubin and risk of kernicterus. Use with caution in significantly jaundiced neonates (total serum bilirubin approaching exchange transfusion thresholds). Monitor bilirubin levels. This risk is lower than with ceftriaxone (which is >90% protein-bound and actively contraindicated in jaundiced neonates) but cannot be disregarded entirely.
• ⚠️ Sodium load: Each gram of cefoxitin sodium contains ~2.3 mEq sodium. For a 1 kg preterm neonate receiving 40 mg/kg q12h: 0.08 g/day = negligible sodium load. For a 3.5 kg term neonate at 40 mg/kg q8h: 0.42 g/day ≈ 1 mEq Na⁺/day — generally acceptable but monitor in fluid-restricted neonates.
• NEC context (specific neonatal indication): In NEC stage II–III (Bell staging) requiring surgical intervention or when there is concern for peritoneal contamination, cefoxitin provides useful combined aerobic + anaerobic coverage. In Indian NICUs, the more commonly used regimen for surgical NEC is piperacillin-tazobactam ± metronidazole or meropenem + metronidazole. Cefoxitin is an alternative when these are unavailable or when the organism is specifically susceptible.

---

Primary Indications — Paediatric (Approved / Standard in India)

---

Paediatric Primary Indication 1: SURGICAL PROPHYLAXIS — Clean-Contaminated and Contaminated Procedures in Children

1. When to prefer cefoxitin over alternatives: Same as adult — when anaerobic coverage is needed for contaminated/clean-contaminated surgery. For paediatric appendectomy (most common indication in children), cefoxitin provides single-agent aerobic + anaerobic coverage superior to cefazolin alone.
2. Preferred alternative if cefoxitin unavailable: Cefazolin + metronidazole (both NLEM-listed, available in government paediatric surgery settings). Metronidazole paediatric IV dose: 7.5 mg/kg.
3. NLEM status: NOT NLEM. Cefazolin and metronidazole are NLEM alternatives.
4. IAP guidance: IAP (Indian Academy of Pediatrics) does not have specific guidance on cefoxitin for surgical prophylaxis. General paediatric surgical prophylaxis recommendations follow adult surgical infection society principles with weight-adjusted dosing.
5. Re-dosing in prolonged paediatric surgery: ⚠️ Even more critical than in adults — children’s higher weight-normalised renal clearance means drug levels may decline faster. Re-dose at 2-hour intervals during surgery.

---

Paediatric Primary Indication 2: INTRA-ABDOMINAL INFECTIONS — Community-Acquired (Paediatric)

1. When to prefer over alternatives in children:
   • (a) Advantage: Single-agent coverage without need for metronidazole (fewer drugs, simplified paediatric IV regimen). In children with limited IV access (single lumen), reducing the number of infusion drugs is practically important.
   • © Compared against: Ceftriaxone + metronidazole (most commonly used in Indian paediatric practice), piperacillin-tazobactam, ampicillin-sulbactam + metronidazole.
   • No specific advantage over ceftriaxone + metronidazole in terms of outcomes — choice is based on institutional protocol and single-agent convenience.
2. When NOT to use:
   • Healthcare-associated / nosocomial infections in paediatric ICU (risk of Pseudomonas, ESBL with porin loss, Enterococcus).
   • Neutropenic children (need broader empirical coverage including anti-pseudomonal activity).
   • Suspected TB peritonitis.
3. NLEM status: NOT NLEM. Ceftriaxone and metronidazole (NLEM alternatives) are available in government paediatric hospitals.
4. Time to clinical response: Defervescence and improving abdominal findings within 48–72 hours of source control + antibiotics. Failure to improve: obtain imaging, reassess source control, broaden coverage.
5. Mandatory baseline investigations: MANDATORY: CBP, serum creatinine, blood cultures (if febrile/septic), peritoneal/abscess fluid culture. RECOMMENDED: CRP, serum lactate (if septic), USG/CT abdomen.
6. Specialist initiation: Paediatric surgeon involvement recommended for all complicated intra-abdominal infections in children. Infectious disease consultation for culture-directed de-escalation in ESBL infections.
7. Indian guideline source: IAP treatment guidelines on surgical infections (general recommendations); AIIMS paediatric surgery antimicrobial protocols.
8. Key disease-specific safety warning: ⚠️ Monitor for C. difficile–associated diarrhoea, especially if concurrent proton pump inhibitor use. ⚠️ In perforated appendicitis with peritonitis, adequate surgical drainage is paramount — no antibiotic alone compensates for inadequate source control.

---

Paediatric Primary Indication 3: PELVIC INFLAMMATORY DISEASE — Adolescents

• ⚠️ Always rule out pregnancy and ectopic pregnancy before treatment — pregnancy test MANDATORY regardless of patient’s reported sexual history.
• ℹ️ Doxycycline is generally avoided in children <8 years due to dental staining risk. In adolescents (≥12 years), doxycycline is safe and appropriate for the 14-day PID course.
• Probenecid may cause nausea/vomiting — administer with food. If vomiting occurs within 30 minutes of probenecid ingestion, consider re-dosing probenecid.
• Partner treatment and STI screening: Same as adult PID — partner notification essential. Screen for HIV, syphilis, Hepatitis B. Consider child protection / POCSO Act implications if patient is a minor — document and report as mandated by law.
• Specialist involvement: Paediatric gynaecology or adolescent medicine specialist recommended for PID in adolescents.

---

Paediatric Primary Indication 4: SKIN & SOFT TISSUE INFECTIONS, UTI, LRTI (Paediatric) — Combined

• SSTI: 7–14 days (bite wounds: 5–7 days if uncomplicated; 10–14 days if complicated).
• UTI: 7–14 days (complicated/febrile UTI).
• LRTI: 7–14 days (aspiration pneumonia).

1. When to prefer over alternatives: No specific paediatric advantage over first-line agents. Consider only when culture-directed or when mixed aerobic-anaerobic coverage needed as a single agent.
2. When NOT to use: Empirical monotherapy without culture guidance. MRSA SSTI (add vancomycin or use clindamycin/TMP-SMX). Nosocomial UTI/pneumonia (need broader coverage).
3. NLEM status: NOT NLEM. Amoxicillin-clavulanate (oral SSTI/UTI in children) and ceftriaxone (IV, NLEM-listed) are preferred first-line agents.
4. IAP guidance: IAP does not specifically recommend cefoxitin for these paediatric indications. Standard IAP guidance for paediatric UTI, SSTI, and pneumonia uses first-line agents (amoxicillin-clavulanate, ceftriaxone, cefuroxime).

---

Secondary Indications — Paediatric (Off-label)

---

Paediatric Secondary Indication 1: ESBL-Producing Enterobacterales — Carbapenem-Sparing Strategy in Children

• Must confirm in-vitro cefoxitin susceptibility — do NOT use empirically.
• Indian paediatric ESBL prevalence is very high (50–80% of E. coli in some paediatric tertiary centre data). Carbapenem-sparing strategy is critically important to slow CRE emergence.
• Best evidence in children is for ESBL UTI (high urinary drug concentrations, low inoculum). For BSI: use as de-escalation from carbapenem after clinical improvement.

---

Paediatric Secondary Indication 2: Necrotising Enterocolitis (NEC) — Neonates

• Cefoxitin is NOT a standard first-line for NEC in most Indian NICUs. Standard regimens include ampicillin + gentamicin + metronidazole or piperacillin-tazobactam + amikacin.
• Cefoxitin’s niche is as a single-agent aerobic + anaerobic coverage alternative — reduces the number of drugs needed (eliminates need for separate metronidazole).
• ⚠️ Monitor renal function closely in neonates with NEC — often associated with haemodynamic instability and AKI, which will markedly prolong cefoxitin half-life.
• ⚠️ Sodium load consideration in neonates receiving high volumes of parenteral fluids.

---

RENAL ADJUSTMENT

---

---

Adult Renal Adjustment Table

---

Paediatric Renal Adjustment

---

Augmented Renal Clearance (ARC)

---

HEPATIC ADJUSTMENT

---

• Assess renal function rigorously — serum creatinine is often falsely low in cirrhotics (low muscle mass, high bilirubin interferes with some creatinine assays). Use cystatin C-based eGFR if available, or measured 24-hour CrCl.
• If hepatorenal syndrome is present: dose as per renal adjustment table.
• Monitor coagulation parameters (PT/INR) — cefoxitin, like some other cephalosporins/cephamycins, can rarely cause hypoprothrombinaemia by interfering with vitamin K–dependent clotting factor synthesis, particularly in malnourished/vitamin K–deficient patients (common in advanced cirrhosis). Consider prophylactic vitamin K (10 mg IV/IM weekly) if prolonged cefoxitin therapy is required in cirrhotic patients with baseline coagulopathy.

---

CONTRAINDICATIONS

---

---

Allergy Cross-Reactivity — Beta-Lactam Antibiotics & Cefoxitin

• Cross-reactivity between penicillins and cephalosporins/cephamycins is driven primarily by R1 (C-7) side chain structural similarity, not by the shared beta-lactam nucleus.
• The overall rate of cross-reactivity between penicillins and cephalosporins is approximately 1–2% for IgE-mediated reactions when side chains are dissimilar.
• Cefoxitin has a unique R1 side chain (thiophene-2-acetyl group with 7-alpha-methoxy substitution) that is NOT shared with any commonly used penicillin or most cephalosporins, resulting in LOW cross-reactivity to most other beta-lactams.

• ℹ️ Beta-lactam allergy skin testing is available at some Indian tertiary centres (AIIMS, CMC Vellore, PGIMER, Sanjay Gandhi PGIMS) but NOT widely available at district or PHC level.
• In the absence of skin testing: For patients with a history of mild, non-anaphylactic penicillin/cephalosporin allergy (rash, itching — not urticaria/angioedema), cefoxitin may be administered with the first dose given under observation (patient monitored for 30 minutes post-injection; resuscitation tray with adrenaline 1:1000, IV fluids, and airway equipment available).
• For patients with a history of anaphylaxis to any penicillin: cefoxitin has low but non-zero cross-reactivity (~1–2%). Administer under observation OR use a graded dose challenge protocol (10% of dose → wait 30 min → remaining 90% of dose → observe 60 min) if the clinical need for cefoxitin is strong and alternatives are not available.
• For patients with anaphylaxis to a cephalosporin sharing a similar R1 side chain with cefoxitin (none of the commonly used cephalosporins share cefoxitin’s R1 — this scenario is very rare): avoid cefoxitin.

---

CAUTIONS

---

⚠️ High-Priority Cautions

• Cefoxitin is 85% renally eliminated as unchanged drug. Accumulation occurs with declining renal function.
• Risk: Neurotoxicity (encephalopathy, myoclonus, seizures), haematological toxicity (leucopaenia, thrombocytopenia).
• Monitoring required: Serum creatinine and eGFR before each dose adjustment. Dose reduction/interval extension mandatory per renal adjustment table (see Part 3). In ICU: consider daily renal function assessment. Watch for clinical signs of neurotoxicity (altered sensorium, myoclonus, seizure activity) in patients with changing renal function.

• Cross-reactivity risk is low (~1–2%) but non-zero.
• Monitoring required: Administer first dose under direct observation for ≥30 minutes. Have adrenaline (epinephrine) 1:1000 IM, IV fluids, and airway equipment available. Monitor for urticaria, angioedema, bronchospasm, hypotension within first hour.

• Beta-lactam neurotoxicity (including seizures) is primarily seen in renal impairment with drug accumulation but can occur at standard doses in patients with pre-existing seizure disorder, structural CNS lesions, or concurrent proconvulsant medications.
• Monitoring required: Maintain dose adjustment for renal function. Observe for new-onset seizure activity. Ensure antiepileptic medications are continued at therapeutic doses.

• All broad-spectrum antibiotics, including cefoxitin, disrupt colonic flora and can precipitate C. difficile–associated diarrhoea/colitis (CDAD).
• Risk factors for CDI: prior CDI episode, recent hospitalisation, age >65, PPI use, immunosuppression, prolonged antibiotic duration.
• Monitoring required: Monitor stool frequency and consistency. Test for C. difficile toxin (GDH + toxin EIA or NAAT) if ≥3 watery stools/day or bloody diarrhoea during or within 8 weeks of cefoxitin therapy. ⛔ Discontinue cefoxitin if CDI is confirmed and switch to a non-CDI-precipitating antibiotic if continued antibacterial therapy is needed.

• Cephamycins (including cefoxitin) contain the N-methylthiotetrazole (NMTT) side chain at the C-3 position — although cefoxitin’s NMTT-like moiety is less potent than that of cefotetan or cefamandole, it can rarely interfere with vitamin K metabolism and clotting factor synthesis.
• Risk factors: Malnutrition, hepatic disease, vitamin K deficiency, concurrent anticoagulants, prolonged therapy (>7–10 days), elderly patients, patients on parenteral nutrition without vitamin K supplementation.
• Monitoring required: Check PT/INR at baseline and periodically (every 3–5 days) during prolonged therapy in at-risk patients. Consider prophylactic vitamin K 10 mg IV/IM weekly if treatment duration exceeds 1 week in at-risk patients.

• Particularly aminoglycosides (gentamicin, amikacin), which are frequently co-prescribed with cefoxitin in surgical infections and PID.
• Additive nephrotoxicity risk, especially in elderly, dehydrated, or pre-existing CKD patients.
• Monitoring required: Serum creatinine every 48 hours during combination therapy. Therapeutic drug monitoring of aminoglycoside levels. Ensure adequate hydration.

---

Standard Cautions

• Reduced renal reserve (often masked by low muscle mass → “normal” creatinine). See Elderly section below for details.
• Increased risk of CDI, neurotoxicity, and thrombophlebitis.

• Standard doses may produce subtherapeutic tissue concentrations. Consider higher prophylactic doses (2–3 g). PK data in morbidly obese Indian patients is limited.

• Rare potentiation of anticoagulant effect via vitamin K metabolism interference (see High-Priority Caution #5). With DOACs: no direct interaction, but monitor for bleeding if renal function is fluctuating (both cefoxitin and DOACs are renally cleared).

• Cefoxitin sodium contains ~2.3 mEq Na⁺ per gram. At standard therapeutic doses (6–8 g/day): ~14–18 mEq Na⁺/day from drug alone. At high doses (12 g/day for NTM): ~28 mEq Na⁺/day. Clinically relevant in heart failure (NYHA III–IV), decompensated cirrhosis with ascites, or oliguric renal failure with fluid overload.

• Immature renal function, higher Vd, risk of bilirubin displacement (though lower than ceftriaxone). See Neonatal Dosing in Part 3.

• May exacerbate colitis or be confused with IBD flare. Monitor stool carefully and investigate for CDI before attributing diarrhoea to IBD flare alone.

---

PREGNANCY

---

LACTATION

---

ELDERLY

---

MAJOR DRUG INTERACTIONS

---

MODERATE DRUG INTERACTIONS

---

COMMON ADVERSE EFFECTS

---

SERIOUS ADVERSE EFFECTS

---

⚠️ Signature ADR: Clostridioides difficile–Associated Diarrhoea / Colitis (CDAD)

---

Other Serious Adverse Effects

---

LABORATORY TEST INTERFERENCE

• ℹ️ Jaffé creatinine interference is the most commonly encountered and clinically impactful laboratory interaction in Indian practice. Alert the laboratory and treating physicians when ordering serum creatinine for patients on cefoxitin. Write on the laboratory request form: “Patient on cefoxitin — request enzymatic creatinine if available; if Jaffé method used, interpret with caution.”
• ℹ️ Urine glucose false-positive with Benedict’s reagent is highly relevant at PHC/CHC level in India where glucose oxidase dipsticks may not be routinely available. Educate laboratory technicians about this interference.
• ℹ️ Blood bank notification: If a patient on cefoxitin requires blood transfusion, proactively inform the blood bank about cefoxitin therapy to prevent delays in cross-matching due to positive DAT.

---

MONITORING REQUIREMENTS

---

Baseline (Before Starting)

---

After Initiation / Dose Change

---

Long-Term / Maintenance Monitoring

• Confirm with enzymatic creatinine assay if possible.
• If enzymatic assay unavailable: draw creatinine at trough (just before next dose, when serum drug levels are lowest).
• Correlate with clinical indicators: urine output, fluid balance, physical examination.
• ⛔ Do NOT reflexively discontinue cefoxitin for a rising creatinine without verifying the assay method and clinical context.

---

PATIENT COUNSELLING

---

---

• Through a drip in your vein (intravenous — IV), usually over 15–30 minutes, OR
• As an injection into your muscle (intramuscular — IM).
• You cannot take this medicine by mouth — it only works when given by injection.
• Your nurse will give you this medicine every 6–8 hours (3–4 times a day), or as a single injection before surgery, depending on your condition."

---

• Tell your nurse or doctor as soon as you notice.
• Do not worry — the next dose can usually be given a little early to catch up.
• Never ask for a ‘double dose’ to make up for a missed one."

---

• Pain, redness, or swelling where the drip or injection was given — this is common. Tell the nurse if it is very painful so they can change the drip site.
• Loose stools or mild diarrhoea — this happens because the medicine can affect normal gut bacteria. Drink plenty of fluids. If diarrhoea becomes severe (more than 3 watery stools a day) or you see blood in your stool, tell your doctor immediately.
• Mild nausea — usually improves after the first day.
• Itching or a mild rash — tell your doctor, who will check if it is an allergy or just a harmless side effect.
• Vaginal itching or white discharge (in women) — this can happen because the medicine affects normal vaginal bacteria. Your doctor can prescribe treatment for this.

---

• Difficulty breathing, swelling of face/lips/tongue, severe hives, or feeling faint — these could be signs of a serious allergic reaction (this is rare but needs immediate treatment).
• Severe watery diarrhoea (more than 3 times a day), bloody diarrhoea, or diarrhoea with stomach cramps and fever — this could be a serious gut infection called C. difficile and needs urgent treatment.
• Unusual bleeding or bruising — nosebleeds, blood in urine, black tarry stools, or bruising without injury.
• Confusion, jerking movements of arms/legs, or a seizure (fit) — especially if you have kidney problems.
• Very little urine or no urine output — could mean kidney problems.
• Severe skin rash with blistering, peeling, or mouth sores — very rare but serious; needs emergency care."

---

• Do not take any new medicines (including medicines from a pharmacy, herbal supplements, or Ayurvedic preparations) without telling your doctor — some may interact with this antibiotic.
• If you are diabetic and checking urine sugar: Tell the laboratory technician you are on cefoxitin — this medicine can cause false readings with certain older tests (Benedict’s test). Blood sugar testing or dipstick urine tests are not affected."

---

• The dry powder (before mixing) should be kept in a cool, dry place away from sunlight.
• Once mixed with water for injection, it must be used within a few hours or kept in a refrigerator — your nurse will manage this."

---

• For treating infections: Usually given for 5–14 days depending on the type and severity of infection.
• ⛔ Do not ask your doctor to stop the medicine early just because you feel better — stopping antibiotics too early can cause the infection to come back and make bacteria resistant to treatment.
• ⛔ Do not ask for this antibiotic for future infections without proper evaluation — antibiotics should be chosen by your doctor based on your specific infection."

---

• After you are discharged, come for the follow-up visit as instructed — usually within 1–2 weeks after completing the antibiotic course.
• If you develop diarrhoea within 4–8 weeks after completing this antibiotic, contact your doctor — it could be a late side effect."

---

Common Patient Questions Addressed

---

Caregiver/Family Counselling

• Recognising allergic reactions: Facial swelling, breathing difficulty, widespread hives — call for help immediately if these occur. This is most important after the first dose.
• Monitoring stools: Watch for frequent watery or bloody diarrhoea — report to the nursing station immediately.
• IV drip site care: Do not pull or dislodge the IV cannula. If the area around the drip becomes red, painful, or swollen, inform the nurse.
• For caregivers of elderly patients: Watch for confusion, unusual sleepiness, or jerking movements — these could indicate drug accumulation (especially if the patient has kidney problems). Report immediately.
• For caregivers of children: Reassure the child that the injection is necessary for their recovery. Observe for rash, diarrhoea, or refusal to feed — report to the nursing team."

---

India-Specific Adherence Support

---

BRANDS AVAILABLE IN INDIA

---

---

---

PRICE RANGE (INR)

---

---

---

---

CLINICAL PEARLS

---

---

---

---

---

---

---

VERSION

---

REFERENCES

1. CDSCO Product Insert: Cefox (Cefoxitin Sodium for Injection IP), Aristo Pharmaceuticals Pvt Ltd. Prescribing information. (Accessed June 2025.)
2. Indian Pharmacopoeia 2018 (8th Edition). Indian Pharmacopoeia Commission. Monograph: Cefoxitin Sodium.
3. NLEM India 2022 (National List of Essential Medicines). Ministry of Health and Family Welfare, Government of India. (Cefoxitin NOT listed — confirmed by review of the complete 2022 list.)
4. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Chapter: Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics. (Brunton LL, Hilal-Dandan R, Knollmann BC, eds.) — Used for pharmacology depth, PK-PD targets, mechanism of action, antimicrobial spectrum, and cross-reactivity analysis.
5. Harrison’s Principles of Internal Medicine, 21st Edition (2022). Chapter: Treatment and Prophylaxis of Bacterial Infections; Chapter: Pelvic Inflammatory Disease; Chapter: Intra-Abdominal Infections. (Kasper DL, Fauci AS, et al.)
6. API Textbook of Medicine, 12th Edition (2022). Association of Physicians of India. Chapters on: Surgical Infections, Intra-Abdominal Infections, Pelvic Inflammatory Disease, Antimicrobial Therapy.
7. ICMR Annual Report on Antimicrobial Resistance (2022). Indian Council of Medical Research, Antimicrobial Resistance Surveillance & Research Network (AMRSN). — Used for Indian ESBL prevalence data, resistance context.
8. FOGSI Clinical Practice Guidelines: Guidelines on Antimicrobial Prophylaxis in Gynaecological Surgery; Guidelines on Management of Pelvic Inflammatory Disease. Federation of Obstetric and Gynaecological Societies of India. (2019–2023 editions.)
9. CDC Sexually Transmitted Infections Treatment Guidelines, 2021. Centers for Disease Control and Prevention. — Used for PID treatment regimen (cefoxitin + doxycycline protocol), widely adopted in Indian obstetric practice per FOGSI endorsement.
10. ATS/IDSA Guideline 2020: Treatment of Nontuberculous Mycobacterial Pulmonary Disease. Daley CL, Iaccarino JM, Lange C, et al. Clin Infect Dis 2020;71(4):e1–e36. — Used for M. abscessus dosing recommendations.
11. Lee CH, Su LH, Tang YF, Liu JW. Treatment of ESBL-producing Escherichia coli bacteraemia with carbapenems or flomoxef: a retrospective study. Antimicrob Agents Chemother 2006;50(11):3804–3805. — Referenced for ESBL carbapenem-sparing evidence (flomoxef/cephamycin class).
12. Matsumura Y, Yamamoto M, Nagao M, et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother 2015;59(9):5107–5113. — Referenced for ESBL carbapenem-sparing evidence.
13. ASHP/IDSA/SIS Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery (Bratzler DW, Dellinger EP, et al., Am J Health Syst Pharm 2013;70:195–283). — Used for surgical prophylaxis dosing, re-dosing intervals, obesity dosing, and duration recommendations. Adapted to Indian context.
14. NeoFax / Lexicomp Pediatric & Neonatal Dosage Handbook — Factual neonatal dosing data used for extrapolation of cefoxitin neonatal dosing recommendations.
15. IAP (Indian Academy of Pediatrics) Treatment Guidelines — General paediatric antimicrobial prescribing guidance. (IAP does not have specific cefoxitin-focused guidance.)
16. Pharmacovigilance Programme of India (PvPI) — CDSCO. ADR reporting guidance and contact information. https://www.cdsco.gov.in
17. NPPA (National Pharmaceutical Pricing Authority) — Verified NLEM pricing and price control status for cefoxitin. (Not NPPA-controlled, confirmed June 2025.)
18. PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — Product list reviewed (June 2025). Cefoxitin not listed.

---